Literature DB >> 10891108

A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.

H Ji1, W Zhang, Y Zhou, M Zhang, J Zhu, Y Song, J Lü.   

Abstract

The three-dimensional structure of lanosterol 14alpha-demethylase (P450(14DM), CYP51) of Candida albicans was modeled on the basis of crystallographic coordinates of four prokaryotic P450s: P450BM3, P450cam, P450terp, and P450eryF. The P450(14DM) sequence was aligned to those of known proteins using a knowledge-based alignment method. The main chain coordinates of the core regions were transferred directly from the corresponding coordinates of P450BM3. The side chain conformations of the core regions were determined by the conformations of the equivalent residues with the highest homologous scores in four crystal structures. The model was then refined using molecular mechanics and molecular dynamics. The reliability of the resulting model was assessed by Ramachandran plots, Profile-3D, hydropathy plot analysis, and by analyzing the consistency of the model with the experimental data. The structurally and functionally important residues such as the heme binding residues, the residues interacting with redox-partner protein and/or involved in electron transfer, the residues lining substrate access channel, and the substrate binding residues were identified from the model. These residues are candidates for further site-directed mutagenesis and site-specific antipeptide antibody binding experiments. The active analogue approach was employed to search the pharmacophoric conformations for 14 azole antifungals. The resulting bioactive conformations were docked into the active site of lanosterol 14alpha-demethylase of Candida albicans. All 14 azole antifungals are shown to have a similar docking mode in the active site. The halogenated phenyl group of azole inhibitors is deep in the same hydrophobic binding cleft as the 17-alkyl chain of substrate. The pi-pi stacking interaction might exist between halogenated phenyl ring of inhibitors and the aromatic ring of residue Y132. The long side chains of some inhibitors such as itraconazole and ketoconazole surpass the active site and interact with the residues in the substrate access channel. To compare with mammalian enzymes, structurally selective residues of the active site of fungal lanosterol 14alpha-demethylase are distributed in the C terminus of F helix, beta6-1 sheet and beta6-2 sheet.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891108     DOI: 10.1021/jm990589g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

1.  Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors.

Authors:  L M Podust; T L Poulos; M R Waterman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 2.  Critical annotations to the use of azole antifungals for plant protection.

Authors:  H Hof
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  The A395T mutation in ERG11 gene confers fluconazole resistance in Candida tropicalis causing candidemia.

Authors:  Jingwen Tan; Jinqing Zhang; Wei Chen; Yi Sun; Zhe Wan; Ruoyu Li; Wei Liu
Journal:  Mycopathologia       Date:  2014-11-15       Impact factor: 2.574

4.  S279 point mutations in Candida albicans Sterol 14-α demethylase (CYP51) reduce in vitro inhibition by fluconazole.

Authors:  Andrew G S Warrilow; Jonathan G L Mullins; Claire M Hull; Josie E Parker; David C Lamb; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Biological spectra analysis: Linking biological activity profiles to molecular structure.

Authors:  Anton F Fliri; William T Loging; Peter F Thadeio; Robert A Volkmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-29       Impact factor: 11.205

6.  Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding.

Authors:  Chunquan Sheng; Zhenyuan Miao; Haitao Ji; Jianzhong Yao; Wenya Wang; Xiaoying Che; Guoqiang Dong; Jiaguo Lü; Wei Guo; Wannian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

7.  Evolutionary trace analysis of CYP51 family: implication for site-directed mutagenesis and novel antifungal drug design.

Authors:  Chunquan Sheng; Shuanghong Chen; Haitao Ji; Guoqiang Dong; Xiaoyin Che; Wenya Wang; Zhenyuan Miao; Jianzhong Yao; Jiaguo Lü; Wei Guo; Wannian Zhang
Journal:  J Mol Model       Date:  2009-07-11       Impact factor: 1.810

8.  Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.

Authors:  Luiz R Basso; Charles E Gast; Igor Bruzual; Brian Wong
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

9.  Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.

Authors:  Jennifer R Pace; Albert M DeBerardinis; Vibhavari Sail; Silvia K Tacheva-Grigorova; Kelly A Chan; Raymond Tran; Daniel S Raccuia; Robert J Wechsler-Reya; M Kyle Hadden
Journal:  J Med Chem       Date:  2016-04-06       Impact factor: 7.446

10.  The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease.

Authors:  Oliver Hucke; Michael H Gelb; Christophe L M J Verlinde; Frederick S Buckner
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.